-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the best method of clinical management of Helicobacterrobacteria is not clear.
recently conducted an audit of clinical treatment data for Helicobacter pyridobacteria in Europe since 2013 to ensure that clinical practice meets the best standards of care.
Data collection for this study, which began in 2013, aims to assess the results of clinical management of Helicobacter pyridosis in Europe, including demographics, previous eradication attempts, treatment options, adverse events and results.
study data from 30,394 patients in 27 European countries, 21,533 (78%) received first-line experience of Helicobacter pyridobacteria treatment.
statistics found that 23% of patients were resistant to kramycin, 32% to methazole and 13% to both.
amoxilin and kramycin were the most common (39 per cent) treatments, with 81.5 per cent of patients achieving treatment eradication.
more than 90% of patients can be eradicated only after receiving a combination or companion therapy.
longer treatment time, high doses of stomach acid inhibitors and higher compliance were associated with higher eradication rates.
time trend analysis shows regional dependence changes in prescriptions in countries, including the abandonment of triple therapy, the use of larger doses of stomach acid inhibitors and longer treatment times, which are associated with increased overall eradication effectiveness (84-90 per cent).
study concluded that only four combination therapies that last at least 10 days in European countries can achieve more than 90% helicobacter pyridobacteria eradication rate, indicating that the European Helicobacter pyridobacteria clinical treatment has a greater heterogeneity, the best clinical treatment guidelines have not been strictly adhered to.
.